Incanthera plc

About Incanthera plc

Incanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. The Company has developed sophisticated formulation and targeting technology platforms to address previously unavailable options across dermatology and oncology. These deliver treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy. Identifying and developing innovative solutions to current clinical, commercially relevant unmet needs, Incanthera combines new technology from industry and leading academics, as well as its in-house development team, with its unique targeting delivery platform. Current Focus: Incanthera’s Skincare Range The Company's current focus is a range of dermatological applications to meet currently unmet needs in the skincare market. Skin + CELL, Incanthera’s unique luxury skincare brand, brings scientifically proven formulations to cosmetics. Enriched with targeted bioactive B3 (an activated form of niacinamide) Skin + CELL’s unique formulations are delivered directly into the skin’s cells to optimise and protect cellular health, energy and protective capabilities. In December 2023, Incanthera announced a commercial skincare deal with Marionnaud Switzerland and Austria (“Marionnaud”), part of the world’s largest health, beauty and lifestyle retailer, A.S. Watson Group for the launch and distribution of Skin + CELL in a planned roll out across Marionnaud’s European store portfolio and subsequent launch across A.S. Watson’s remaining global territories, numbering over 16,000 stores. The Company originated from the Institute of Cancer Therapeutics, University of Bradford and has a portfolio of specific cancer-targeting therapeutics through a pipeline agreement with the Institute of Cancer Therapeutics and other corporate acquisitions. Incanthera’s strategy is to develop or acquire each asset, technology and candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.